Categories
Breast Cancer

Miles for Moffitt race brings two cancer survivors together [Video]

Since 2016, the “Cancer Crushers” race team has raised over $100,000.

TAMPA, Fla. — In May of 2016, Janelle Morales finished her treatment for breast cancer. Coincidently, the Miles for Moffit race began that month.

“I think that I am very fortunate that I had early-stage breast cancer, but I felt like Miles for Moffitt and forming the team “Cancer Crushers”, was my way of giving back and saying the fight doesn’t stop with me,” Morales said. “I’ve got to continue this.” 

She says since 2016 her team “Cancer Crushers” has raised over $100,000. 

Three-time cancer survivor, Lisa Assetta, who was treated at Moffitt, reached out on the Cancer Crushers Facebook page in hopes to buy a face mask that caught her eye. She got that and more by striking up a friendship with Morales. They call each other “Survivor Sisters.”

“It’s great to talk to the doctors and the …

Watch/Read More

Most Popular Posts Today

New breast cancer drug delivers unprecedented levels of survival, stopping tumor growth [Video]
►
Categories
Breast Cancer

New breast cancer drug delivers unprecedented levels of survival, stopping tumor growth [Video]

A trial of a newly approved breast cancer drug in patients who are not typically targeted by the drug resulted in extremely encouraging results never seen before. Patients who received the drug survived longer and had lower growth in their tumours than those who received standard chemotherapy. ThePrint’s Sandhya Ramesh explains the findings.Brought to by @Kia India To know more, read: https://theprint.in/health/experimental-drug-shows-success-in-advanced-breast-cancer-patients-better-than-standard-chemo/995701/Subscribe to the Pure Science Telegram Channel https://t.me/PureScienceWithSandhyaRameshSupplementary reading: Modi, S., et al.; The New England Journal of Medicine (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2203690---------------------------------------------------------------------------------------------Join our channel to get access to perks. Click 'JOIN' or follow the link below:https://www.youtube.com/channel/UCuyRsHZILrU7ZDIAbGASHdA/join---------------------------------------------------------------------------------------------Connect with ThePrint» Subscribe to ThePrint: https://theprint.in/subscribe/» Subscribe to our YouTube Channel: https://bit.ly/3nCMpht» Like us on Facebook: https://www.facebook.com/theprintindia» Tweet us on Twitter: https://twitter.com/theprintindia» Follow us on Instagram: https://www.instagram.com/theprintindia» Find us on LinkedIn : https://www.linkedin.com/company/theprint» Subscribe to ThePrint on Telegram: https://t.me/ThePrintIndia» Find us on Spotify: https://spoti.fi/2NMVlnB» Find us on Apple Podcasts: https://apple.co/3pEOta8

Most Popular This Week

Oklahoma Gov. signs bill requiring insurance coverage of diagnostic mammograms [Video]
►
Categories
Breast Cancer

Oklahoma Gov. signs bill requiring insurance coverage of diagnostic mammograms [Video]

Breast cancer survivors and Oklahoma lawmakers are calling it legislation that will save lives. At-risk patients will now get financial help to catch the deadly disease early.Stay informed about Oklahoma news and weather! Follow KFOR News 4 on our website and social channels. https://kfor.com/https://www.youtube.com/c/kfor4newshttps://www.facebook.com/kfor4https://twitter.com/kforhttps://www.instagram.com/kfortv4/

Breast cancer drug Enhertu shows promise against some tumors, opening new treatment possibilities to thousands of patients [Video]
►
Categories
Breast Cancer

Breast cancer drug Enhertu shows promise against some tumors, opening new treatment possibilities to thousands of patients [Video]

A drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.

This vlog contains an auto-curated collection of videos. The videos in this vlog do not necessarily reflect our opinion.